Cargando…

Characterizing patients initiating abaloparatide, teriparatide, or denosumab in a real-world setting: a US linked claims and EMR database analysis

SUMMARY: We characterized patients initiating abaloparatide (ABL), teriparatide (TPTD), or denosumab (DMAB) in a real-world clinical setting from a large medical and pharmacy claims database. Differences were noted in sex, age, pathologic fractures, comorbidity index, and prior bisphosphonate use fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Imel, E.A., Starzyk, K., Gliklich, R., Weiss, R.J., Wang, Y., Williams, S.A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer London 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7661401/ https://www.ncbi.nlm.nih.gov/pubmed/32696118 http://dx.doi.org/10.1007/s00198-020-05388-y

Ejemplares similares

Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: A US administrative claims database study
por: Cosman, F., et al.
Publicado: (2022)

Differential effects of abaloparatide and teriparatide on hip cortical volumetric BMD by DXA-based 3D modeling
por: Winzenrieth, R., et al.
Publicado: (2021)

Teriparatide and Abaloparatide Have a Similar Effect on Bone in Mice
por: Brent, Mikkel Bo, et al.
Publicado: (2021)

Effects of abaloparatide and teriparatide on bone resorption and bone formation in female mice()
por: Arlt, Heike, et al.
Publicado: (2020)

Effect of Denosumab and Teriparatide on Fracture Nonunion
por: Boutin, Regine, et al.
Publicado: (2023)

SUN-385 Differential Effects of Abaloparatide and Teriparatide on Hip Cortical Volumetric BMD by DXA-Based 3d Modeling
por: Winzenrieth, Renaud, et al.
Publicado: (2020)

Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE
por: Eastell, R., et al.
Publicado: (2019)

Abaloparatide versus teriparatide: a head to head comparison of effects on fracture healing in mouse models
por: Bernhardsson, Magnus, et al.
Publicado: (2018)

Abaloparatide is an Effective Treatment Option for Postmenopausal Osteoporosis: Review of the Number Needed to Treat Compared with Teriparatide
por: Reginster, Jean-Yves, et al.
Publicado: (2018)

Comparative study in estrogen-depleted mice identifies skeletal and osteocyte transcriptomic responses to abaloparatide and teriparatide
por: Lv, Zhengtao, et al.
Publicado: (2023)

Abaloparatide Real‐World Patient Experience Study
por: Gold, Deborah T, et al.
Publicado: (2021)

Abaloparatide Exerts Bone Anabolic Effects with Less Stimulation of Bone Resorption-Related Factors: A Comparison with Teriparatide
por: Makino, Akito, et al.
Publicado: (2018)

Abaloparatide exhibits greater osteoanabolic response and higher cAMP stimulation and β‐arrestin recruitment than teriparatide
por: Sahbani, Karim, et al.
Publicado: (2019)

Circulating Osteogenic Progenitor Cells Enhanced with Teriparatide or Denosumab Treatment
por: Giner, Mercè, et al.
Publicado: (2022)

Teriparatide treatment patterns in osteoporosis and subsequent fracture events: a US claims analysis
por: Bonafede, M. M., et al.
Publicado: (2015)

Comparable Initial Engagement of Intracellular Signaling Pathways by Parathyroid Hormone Receptor Ligands Teriparatide, Abaloparatide, and Long‐Acting PTH
por: Sato, Tadatoshi, et al.
Publicado: (2021)

Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis
por: Hong, Pan, et al.
Publicado: (2023)

Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment
por: Hirooka, Yasuaki, et al.
Publicado: (2021)

Efficacy of the Combination of Teriparatide and Denosumab in the Treatment of Postmenopausal Osteoporosis: A Meta-Analysis
por: Sun, Yang, et al.
Publicado: (2022)

Prescription fill rates for acute and chronic medications in claims-EMR linked data
por: Park, Yoonyoung, et al.
Publicado: (2018)

Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States
por: Le, Quang A., et al.
Publicado: (2018)

Effects of denosumab versus teriparatide in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment
por: Hirooka, Yasuaki, et al.
Publicado: (2020)

Pretreatment of daily teriparatide enhances the increase of bone mineral density in cortical bones by denosumab therapy
por: Kamimura, Mikio, et al.
Publicado: (2018)

Circulating noggin levels following treatment with denosumab or teriparatide in postmenopausal women with low bone mass
por: Anastasilakis, Athanasios D., et al.
Publicado: (2019)

Phase 1b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density
por: Miller, Paul D., et al.
Publicado: (2021)

Use of electronic medical records (EMR) for oncology outcomes research: assessing the comparability of EMR information to patient registry and health claims data
por: Lau, Edmund C, et al.
Publicado: (2011)

Abaloparatide and the Spine: A Narrative Review
por: Thompson, Jeremy C, et al.
Publicado: (2020)

The impact of sequential therapy from short-term teriparatide to denosumab compared with denosumab alone in patients with osteoporotic hip fracture: a 1-year follow-up study
por: Park, Chan Ho, et al.
Publicado: (2020)

The Effect of Zoledronic Acid on Bone Microarchitecture and Strength after Denosumab and Teriparatide Administration: DATA‐HD Study Extension
por: Ramchand, Sabashini K., et al.
Publicado: (2022)

In the digital world of the EMR, Open Notes change everything
por: Roter, Debra L
Publicado: (2015)

Two-year clinical outcome of denosumab treatment alone and in combination with teriparatide in Japanese treatment-naive postmenopausal osteoporotic women
por: Nakamura, Yukio, et al.
Publicado: (2017)

Clinical efficacy of denosumab, teriparatide, and oral bisphosphonates in the prevention of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis
por: Yuan, Chuanjian, et al.
Publicado: (2023)

Real-World Investigation of Eosinophilic-Associated Disease Overlap (REVEAL): Analysis of a US Claims Database
por: Brailean, Anamaria, et al.
Publicado: (2023)

EmrE reminds us to expect the unexpected in membrane transport
por: Grabe, Michael, et al.
Publicado: (2019)

Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide
por: McClung, Michael R., et al.
Publicado: (2017)

Antiresorptive-associated spontaneous fractures of both tibiae, followed by an atypical femur fracture during the sequential treatment with alendronate, denosumab then teriparatide
por: Tan, Juan, et al.
Publicado: (2019)

Profile of Abaloparatide and Its Potential in the Treatment of Postmenopausal Osteoporosis
por: Tella, Sri Harsha, et al.
Publicado: (2017)

302 Abaloparatide as a novel therapy for posttraumatic osteoarthritis
por: Landgrave, Samantha H., et al.
Publicado: (2022)

S107. HEALTHCARE UTILIZATION AND COST IN SCHIZOPHRENIA AND BIPOLAR DISORDER: REAL-WORLD EVIDENCE FROM US CLAIMS DATABASES
por: Greene, Mallik, et al.
Publicado: (2018)

Real-World Characterization of Women with Diagnosed Endometriosis Initiating Therapy with Elagolix Using a US Claims Database
por: Surrey, Eric S, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_raj3sn8ubu5925v4fsm5so01b4